ASCML
ACAD icon

ADKINS SEALE CAPITAL MANAGEMENT LLC’s Acadia Pharmaceuticals ACAD Stock Holding History

ADKINS SEALE CAPITAL MANAGEMENT LLC’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.59K Hold
300
– – 0.01% 209
2026
Q1 		$6.68K Hold
300
– – 0.01% 201
2025
Q4 		$8.01K Buy
+300
New +$7.17K 0.01% 199

Other funds holding ACAD

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

ADKINS SEALE CAPITAL MANAGEMENT LLC's ACAD Position: Q2 2026 in Review

ADKINS SEALE CAPITAL MANAGEMENT LLC held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 300 shares worth $7.59K. The position accounts for 0.01% of the portfolio, ranked #209.

ADKINS SEALE CAPITAL MANAGEMENT LLC first reported a position in ACAD in Q4 2025 and has held it in 3 quarters since. The position peaked at $8.01K in Q4 2025. 121 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • ADKINS SEALE CAPITAL MANAGEMENT LLC held 300 shares of Acadia Pharmaceuticals worth $7.59K as of Q2 2026.
  • ADKINS SEALE CAPITAL MANAGEMENT LLC left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
  • Acadia Pharmaceuticals made up 0.01% of ADKINS SEALE CAPITAL MANAGEMENT LLC's portfolio in Q2 2026, its #209 holding.
  • ADKINS SEALE CAPITAL MANAGEMENT LLC first reported a position in Acadia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • ADKINS SEALE CAPITAL MANAGEMENT LLC's Acadia Pharmaceuticals position peaked at $8.01K in Q4 2025.
  • 121 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on ADKINS SEALE CAPITAL MANAGEMENT LLC's 13F filing for Q2 2026, filed 5 Aug 2026.